Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp Alfa and PDS01ADC With or Without SBRT in Metastatic Non-Prostate Genitourinary Malignancies
NCT04235777Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2020
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of bintrafusp alfa and NHS-IL-12 in genitourinary cancer (3 arms), sponsored by National Cancer Institute. Primary endpoint: Safety and Tolerability. Started Jul 2020; status: active, not recruiting.
02
Drugs
bintrafusp alfaNHS-IL-12
03
Conditions
genitourinary cancer
Beyond the preview
Go deeper on NCT04235777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04235777.